BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-03-31

Reporting Person: Thackray Helen M. (Director, Chief R&D Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-31	Common Stock	A	100000	—	Acquired	100000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-31	Emp. Stock Option (Right to Buy)	$10.17	A	400000	Acquired	2031-03-31	Common Stock (400000)	Direct

Footnotes

F1: Award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

F2: Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.